ISSN: 2332-0877

Journal des maladies infectieuses et de la thérapie

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Remdesivir for the Treatment of COVID-19 Disease: A Retrospective Comparative Study of Patients Treated with and without Remdesivir

Maulik Soni, Nirav Bapat, Kaivan Shah, Ritanshu Chandarana, Parloop Bhatt, Manish Rana, Amit Patel, Kartikae Sharan, Shayon Ghosh, Vishnu Venugopal, Nitesh Shah, BhagyeshShah, Vipul Thakkar, Rashmi Chovatiya, Hardik Shah, Pradip Dabhi, Minesh Patel, Bhowmik Meghnathi, Vineet Sankhla, Vipul Kapoor, Tejas Patel, Surabhi Madan

Background: Remdesivir (RDV) in coronavirus disease 2019 (COVID-19) has been found to be beneficial in patients with severe disease; however, its role in mild-moderate disease and its optimal timing need to be identified.

Objective: To assess the course of illness and final outcome in patients who received RDV at various stages of illness, and compare it to the non-RDV group.

Methods: This is a retrospective data analysis of 1262 COVID-19 patients hospitalized from May 5, 2020 to August 31, 2020. The primary outcomes were progression to Mechanical Ventilation (MV) or death. Kaplan Meier survival analysis and log rank test were used for evaluating primary outcomes.

Results: 398 patients comprised the RDV group and 260 patients comprised the non-RDV group. 2/3rd of patients were above 50 years of age in both the groups and 3/4th patients were male. Mortality rate was 5.8% in RDV group (10.4% in non-RDV group). Mortality rate was 3.6%, 4% and 16.7% when RDV was started within 5 days, 5 to 10 days and after 10 days of symptom onset respectively. Fewer patients in RDV group progressed to MV (4.0% v/s 8.2%). Earlier discharge occurred in RDV group. Use of supplemental oxygen was observed in 44.7% patients in RDV group (54.2% in non-RDV group). No significant adverse events were observed with RDV. Survival analysis showed that probability of event (death) was significant for patients with Hypertension (HT) and/or Diabetes Mellitus (DM) in RDV group.

Conclusion: Early initiation of RDV is associated with shorter hospital stay, lower mortality as well as reduced need for supplemental oxygen and mechanical ventilation.

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié.